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In recent years, accumulating experimental evidence supports the notion that diabetic patients may greatly beneﬁt from cell-based
therapies, which include the use of adult stem and/or progenitor cells. In particular, mesenchymal stem cells and the circulating
pool of endothelial progenitor cells have so far been the most studied populations of cells proposed for the treatment of vascular
complications aﬀecting diabetic patients. We review the evidence supporting their use in this setting, the therapeutic beneﬁts that
these cells have shown so far as well as the challenges that cell-based therapies in diabetic complications put out.
1.Introduction
Theworldwideincreaseintheprevalenceofdiabetesmellitus
reinforces the search for solutions to prevent it as well as to
oppose the development and theprogression of its complica-
tions. Particularly, the increasing prevalence of diabetes mel-
litus (DM) now aﬀects adolescents and younger adults, thus
promoting an earlier development of invalidating chronic
diseases [1]. Experimental evidence suggests that cell-based
therapies might represent a new and promising strategy
for the treatment of diabetic vascular complications, and
growing interest has recently been focused on mesenchymal
stem cells and endothelial progenitor cells. Both cells types
not only act against the mechanisms underlying diabetic
complications but also rescue the abnormalities that stem
cells present in diabetic patients, which contribute to the
vascular complications. Notably, these cells avoid the ethical
issues relating to the use of the embryonic cells. However,
there are concerns about how the diabetic environment
aﬀects these cells. So, additional challenges for these cells
include making them resistant to the diabetic environment
and thus increasing their clinical eﬃcacy [2].
On these premises, we will here review the evidence
suggesting why adult stem/progenitor cells should be used
in diabetic patients, the therapeutic beneﬁts that these cells
seem to oﬀer for treating macrovascular and microvascular
complications,andthechallengesthatcell-basedtherapiesin
DM present.
2. Stem Cells
Adult stem cells comprise of roughly 3 diﬀerent groups: the
bone marrow stem cells (BM-SC), the circulating pool of
stem/progenitor cells (which are also derived from the bone
marrow), and the tissue-resident stem cells. BM-SC can be
further categorized into multipotent adult progenitor cells,
mesenchymal stem cells (MSC), and hematopoietic stem
cells. The circulating pool of stem/progenitor cells includes
diﬀerent types of cells, among which the most studied for
the setting of vascular complications are the endothelial
progenitor cells (EPC). EPC were identiﬁed by Asahara et
al. [3] in the search for circulating angiogenic cells. They
observed that these cells were able to form new blood vessels
and promote neovascularisation after ischemia. Therefore,
these cells seem to be the most promising in the setting
of DM because of their potential utility in therapeutic
neovascularisation and vascular repair. This paper will be
focused on MSC and EPC, since these subsets of cells are the
most studied in the ﬁeld of the cell-based therapies for DM
and for diabetic complications.
MSC are a subset of cells that express on their sur-
face CD54/CD102 (intracellular adhesion molecule), CD1662 Experimental Diabetes Research
(vascular cell adhesion molecule), CD49 (α-integrin) as well
as CD73 (5 ribonucleotide phosphohydrolase) and CD90
whichalsoregulatecell-to-cellinteractions.Theyalsoexpress
CD44 (receptor for hyaluronic acid), CD105 (modulator
of cellular responses to TGF-β), and MHC1, whereas they
do not express CD34, CD14, CD45, CD11a/LFA-1, and
CD31, which are surface markers featuring hematopoietic
cells and/or EPC instead [4]. MSC are present in the bone
marrow, but can also be found in many other fetal and
adult tissues. Indeed, they are generally isolated from bone
marrow, adipose tissue, umbilical cord blood, and compact
bone. MSC display a great therapeutic potential because,
beyond their capability to diﬀerentiate into muscle, neural
precursors, cardiomyocytes, and other cells types, they are
able to migrate and home in injured sites, where they act
both by regenerating tissues and by secreting trophic factors
and paracrine mediators. Moreover, these cells interact with
the immune system, particularly with dendritic cells, T cells
and NK cells and therefore they modulate the outcome of
immune cells responses, apparently by inhibiting TNF-α and
INF-γ and by increasing IL-10 [5]. Therefore, their unique
immunomodulatory properties make these cells appropriate
for both autologous and allogenic transplants, since they
avoid and/or actively suppress the immunological responses
that cause rejection of transplants. For the same reason, they
are now being studied for the treatment of immunological
diseases, among which is type 1 DM [6]. Indeed, in the
non obese diabetic mice “NOD mice”, the injection of MSC
reduced the capacity of diabetogenic T cells to inﬁltrate pan-
creatic islets, thus preventing β-cell destruction [7]. Another
model of type 1 DM is injecting mice with streptozotocin,
which is a drug destroying the β-cells [8]. Also in this
model,MSCwereabletodiﬀerentiateintoinsulin-producing
cells releasing insulin in a glucose-dependent manner and
improving the natural history of diabetes [9, 10]. Moreover,
it has been demonstrated that, when cotransplanted with
islets, MSC improved graft morphology and function by the
promotion of revascularization [11].
EPC are adult hemangioblast-derived cells [12], which
are characterized by the expression of CD34, vascular endo-
thelial growth factor receptor 2 (VEGFR-2), and CD133,
which has been included as marker expressed on primitive
cells but not on diﬀerentiated ones. In fact, as the heman-
gioblasts destined to become endothelial cells diﬀerentiate,
they downregulate the hematopoietic cells marker CD133+
(AC133) expression [12]. EPC can be isolated from human
peripheral or umbilical cord blood and can also be found in
bonemarrowniches.TheinterestinEPCcomesfromthefact
that these cells have been shown to have direct angiogenic
actions and/or to be able to support angiogenesis. Particu-
larly, like for MSC, part of their therapeutic potential could
be related to their ability to secrete paracrine mediators.
In this respect, several studies have shown that these cells
release interleukins, growth factors, and chemokines that
altogether regulate CD14+ cells, accelerate vascular network
formation, and enhance healing processes [2]. Therefore,
theyareapromisingtherapeutictoolinthesettingofdiabetic
complications, which are a consequence of dysfunctional
vascular responses.
3. Rationale for the Use of Adult
Stem/Progenitor Cells for Diabetic
Complications
Diabetic patients exhibit impaired mobilization of adult
stem cells from the bone marrow [13] and dysfunctional
circulating progenitor cells [14, 15]. A growing body of
evidence has demonstrated that DM is associated with a
generalizedreductionincirculatingEPCandthatthisdecline
is linearly correlated with the severity of DM, in terms of
HbA1c and blood glucose, whereas it is inversely related
to glucose control [16–18]. Busik and colleagues suggested
that diabetic neuropathy, altering the circadian rhythm of
bone marrow cells release, could be one of the factors
accounting for the defective mobilization of stem/progenitor
cells coupled to an increased number of cells trapped in
the bone marrow [19]. Apart from diabetic neuropathy,
the factors that have been classically related to impaired
stem/progenitor cells mobilization are the direct and/or
indirect eﬀects of hyperglycemia. Fadini and colleagues have
demonstrated that the bone marrow mobilization of cells
is sensitive to hyperglycemia [13]. Using a model of hind
limbs ischemia-reperfusion (I/R) injury for the study of EPC
mobilisation in type 1 DM, they observed that diabetic rats
were completely unable to mobilise EPC after I/R injury,
compared to the control rats showing a mobilisation curve
within 7 days after injury. However, after insulin administra-
tion and premedication with granulocyte-colony stimulating
factor (G-CSF) and other stem cells factors, they achieved a
partial recovery in postischemic EPC mobilisation [13]. This
study suggests that mobilization mechanism is sensitive to
chronic hyperglycemia and early on remains reversible.
One of the mechanisms involved in the toxic eﬀects of
hyperglycemiaonBM-SCseemstobetheunbalancebetween
nitric oxide (NO) and reactive oxygen species (ROS) [20].
It is known that hyperglycemia increases ROS formation
which, by reacting with NO, lead to a reduction in NO
bioavailability, therefore impairing NO signalling. Moreover,
diabetic BM-SC display uncoupled endothelial NO synthase
(eNOS) activity, promoting the production of ROS and so
increasing the unbalance between ROS and NO [20]. Any
reduction in NO bioavailability is believed crucial for BM-
SCmobilizationsinceNO-mediatedsignallingisessentialfor
activationofMMP-9which,inturn,shiftsresidentcellsfrom
a quiescent to a proliferative state and stimulates their rapid
mobilization into the circulation [21]. Consistent with this
concept, Segal and colleagues showed that incubating dia-
betic CD34+ cells with NO donors corrected their migratory
defect, proving that impaired NO signalling in DM signiﬁ-
cantly contributes to bone marrow dysfunctional responses
[22]. It is reasonable to suggest that MSC migratory proper-
ties could also be aﬀected in DM. Diabetic patients display
increased circulating levels of osteoprotegerin (OPG) [23],
which is a soluble TNF-receptor with atherogenic [24]a n d
diabetogenic [25] actions. Notably this peptide is the decoy
receptor for the TNF-related apoptosis-inducing ligand
(TRAIL) and displays antiatherosclerotic and antidiabeto-
genic properties. Our group has recently shown that TRAILExperimental Diabetes Research 3
is able to promote the migration of BM-MSC in vitro [26].
OPG dose dependently neutralizes the promigratory activity
ofTRAIL[27],sothehighlevelsofOPGobservedindiabetic
patients might impair the pro-migratory signalling driven by
TRAIL, accounting for the abnormalities of BM-SC in DM.
Several in vitro works have pointed out that the diabetic
milieu does not only impair BM-SC mobilization, but it also
aﬀectsthelifespanandthefunctionsofadultstemcellswhich
may account for the reduction in circulating EPC. Particu-
larly, hyperglycemia has been shown on its own to accelerate
the senescence of EPC by the activation of p38/MAPK
[28] and Akt/p53/p21 [29] pathways or by downregulation
of sirtuin 1 [30]. In this setting, the senescence of EPC
could also be due either to the NO reduced bioavailability
mentioned previously, since it has been demonstrated that
NOdelaysendothelialcellssenescencethroughtheactivation
of telomerase [31], or to the increased apoptosis induced by
ROS. It has indeed been demonstrated that the deletion of
p66ShcA, which is a gene regulating the apoptotic responses
to oxidative stress, rescues the EPC defects induced by
hyperglycemia [32]. However, in a work aimed at deﬁning
cross-sectionally the time course of EPC alterations in type 2
DM and to identify potential mechanisms of progenitor cells
reduction, Fadini and colleagues found that the lower the
count of CD34+ cells the higher their apoptotic rate but also
that there was no diﬀerence in the apoptotic rate between
patients with and without DM and that the percentage of
EPC apoptosis was too low to fully explain a decreased cell
count [33]. Thus, in vivo studies have not conﬁrmed yet if
diabetic EPC have a shortened lifespan, and other mech-
anisms, apart from the reduced lifespan, may account for
the reduction of these cells in DM. Likewise, when cultured
in hyperglycemic conditions, MSC increase the production
of intracellular ROS which reduce hypoxia-induced factor1α
(HIF1α) expression and consequently attenuate hypoxia-
induced vascular endothelial growth factor (VEGF)-A and
platelet-derived growth factor (PDGF)-B transcription [34].
Moreover, it is well known that hyperglycemia leads to
nonenzymatic glycosylation of proteins and subsequent
formation of advanced glycation end products (AGEs) that
interacting with their own receptor, RAGE, then activate
several intracellular pathways ultimately leading to tissue
damage [1]. In this setting, AGEs directly impair the
reparative function of both EPC and MSC, and several works
have evaluated AGEs deleterious eﬀects on EPC [35–37]a s
well as on MSC. After isolation of MSC from rats with type
1 DM, Stolzing and colleagues studied their ex vivo ability
to proliferate and diﬀerentiate into the ﬁbroblastic colony-
forming unit. They reported that colony size and number
were signiﬁcantly reduced in diabetic rats, mainly because
of the induction of cell apoptosis and senescence by AGEs
[38]. Consistent with this, when treated with glyceraldehydes
and glycolaldehydes, MSC showed reduced cell proliferation,
increased cell apoptosis, and impaired diﬀerentiation into
adipogenic, chondrogenic, and osteogenic clones. These
eﬀects were partially prevented by the antiserum against
RAGE [35, 39].
Altogether these experimental works demonstrate that
DM aﬀects the mobilization and the functions of adult stem
cells; therefore they provide the rationale for the use of adult
stem cells for diabetic complications.
4. Adult Stem/Progenitor Cells for the
Treatment of MacrovascularComplications
andDiabeticCar dio m y o path y
4.1. Macrovascular Complications. Both type 1 and type 2
DMincreasetheincidenceandprogressionofatherosclerosis
[40] into large arteries and the development of macrovas-
cular complications. Their major clinical manifestations are
coronary artery disease (CAD), peripheral artery disease
(PAD), and stroke. In particular, patients with DM have a 2–
4 fold increased risk of fatal myocardial infarction, PAD and
stroke, together with poorer long-term outcomes [40, 41].
The evidence supporting the utility of cell-based therapies
in this setting, and particularly EPC-based therapies, comes
from clinical studies showing an inverse relation between the
number of EPC and the occurrence of cardiovascular dis-
eases (CVD). Consistent with the reduction of CD133+cells
observed in patients with CVD, CD34+/VEGFR-2+ and
CD133+ cells counts have indeed been shown to predict
the occurrence of CVD in one-year follow-up studies [42,
43], whilst CD34+ and CD34+/KDR+ c e l l sc o u n t sm i g h tb e
helpful in stratifying the cardiovascular risk of the patients
[44]. As expected, in patients with DM and metabolic
syndrome, circulating CD34+ cell numbers were also found
to be an independent risk marker of CVD [45], leading to
the hypothesis that the reduction in circulating progenitors
is not only a marker but also a causative factor for the
increase in cardiovascular events. Interestingly, signiﬁcantly
lower numbers of EPC were observed in diabetic patients
when PAD had developed [46].
Although a study by Ma and colleagues showed that
the treatment with EPC reduced the stenosis obtained
after denudation of the common carotid artery in rabbits
[47], data on the utility of cell-based therapies to prevent
atherosclerosis are indeed conﬂicting. Silvestre and col-
leagues have demonstrated that transplantation of BM-SC in
ischemicApolipoproteinE-knockoutmice,whichisthemost
largely used animal model for the study of atherosclerosis
[41], disappointingly accelerated atherosclerosis without
altering the plaque composition [48]. Moreover, smooth
muscle progenitor cells have been shown to contribute to
the exaggerated intimal hyperplasia found in DM [49].
Consistent with this, in the clinical trials evaluating cell-
based therapies after myocardial infarction, one of the major
side eﬀects that have been observed was the aggravation of
the restenosis [50]. In this setting, another issue that needs
to be further investigated is whether arrhythmias are a real
safety concern, given that a higher number of arrhythmic
events have been reported after intramyocardial delivery of
cells, particularly skeletal myoblasts [51]. However, the trials
aimed at myocardial repair in patients with acute myocardial
infarction have also proven that the intracoronary infu-
sion of BM-SC or CD133+or MSC is associated with an
improvement in the global left ventricular ejection fraction,
a reduction in the end-systolic left ventricular volumes, and4 Experimental Diabetes Research
a better perfusion in the areas of infarction [52, 53]. These
eﬀects are supposed to be due, at least in part, to the ability
ofthesecellstostimulatemyocardialrepair/regenerationand
neovascularisation (Figure 1).
Cell-based therapies appear promising also in the setting
of PAD. A growing body of evidence strongly suggests the
utility and eﬀectiveness of adult stem cells for therapeutic
neovascularisation both in absence [54–57] and in presence
[58–60] of DM. Diabetic PAD is a systemic disease
characterized by occlusion of peripheral arteries together
with a severe impairment in the development of collateral
vessels believed to be caused by endothelial dysfunction and
the lack of growth factors, such as VEGF, both driven by
glucotoxicity [1, 40] .Th ea b i l i tyo fE P Ca n dM S Ct op r od u c e
angiogenic factors (by restoring the physiological levels of
VEGF and HIF1α) and to diﬀerentiate into vascular cells
in the periphery [61] has been implicated in the recovery
of the native blood ﬂow in ischemic hind limbs after their
use. Recently, the transplantation of MSC for therapeutic
neovascularisation has also been proven beneﬁcial in type
1 diabetic patients with bilateral upper extremity digital
gangrene, demonstrating improved arterial perfusion, good
healing of all amputation sites, and cessation of pain [62].
Furthermore, in the context of macrovascular complica-
tions, intravenous autologous MSC transplantation has been
shown to be able to reduce the mortality rate in patients with
ischemic stroke [63].
4.2. Diabetic Cardiomyopathy. Diabetic cardiomyopathy
should be considered separately from the so-called macro-
vascular complications of DM, since it corresponds to
the stage characterized by the development of ventricular
dysfunction in patients aﬀected by DM, in the absence
of CAD, valvular heart disease, or hypertension [64]. Its
features, which are heterogeneous, are mainly due to cell
apoptosis [64]a s s o c i a t e dw i t had r a m a t i cr e d u c t i o ni n
tissue-resident stem cells [65], extensive myocardial ﬁbrosis,
and capillary rarefaction [66]. In particular, it has been
shown that the abnormal myocardial matrix deposition
associated with DM relies on increased collagen synthesis
and on its reduced degradation, whose main eﬀectors are the
metalloproteases (MMP). Consistent with this, the diabetic
myocardium is characterized by decreased activity of MMP-
2, leading to increased collagen accumulation, and increased
activity of the apoptotic factor MMP-9 which is responsible
for apoptosis of endothelial cells, reduction of capillary
density, and poor myocardial perfusion instead. In a study
on rats with type 1 DM, the intravenous infusion of MSC
improved cardiac function through increased angiogenesis
and attenuated cardiac remodelling. Eight weeks after the
induction of DM, rats were infused with MSC, which
then homed into the myocardium and led to increased
myocardial arteriolar density and decreased collagen content
in the diabetic myocardium. Interestingly, increased MMP-2
activity and decreased transcriptional level of MMP9 were
also reported [67]. However, even more fascinating is the
possibility of developing noninvasive cell-based therapies
relying on the trophic activities of MSC (Figure 1). A recent
study with a hamster heart failure model has demonstrated
that an intramuscular delivery of MSC would be suﬃcient
to signiﬁcantly improve ventricular function, enhancing
capillary and myocyte densities, attenuating apoptosis, and
reducing ﬁbrosis. This was reported to be due to a trophic
cross-talk among the injected MSC, the bone marrow, and
the heart [68].
5. Adult Stem/Progenitor Cells for
the Treatment of Microvascular
Complications andWound Healing
5.1. Diabetic Nephropathy. Diabetic nephropathy is now
the most common cause of end-stage renal failure in the
Western societies. The arterial damages and the changes to
the glomerular ultrastructure, mainly mesangial expansion
and glomerular membrane thickening, are the principal
mechanisms causing diabetic nephropathy [1]. These eﬀects
are both driven by hyperglycemia, and thus it is not
surprising that one of the most important interventions in
preventing diabetic nephropathy, or attenuating it, can be
achieved by tight glycemic control [69]. In this setting, it has
been shown that EPC mobilize into damaged glomeruli [70],
possibly participating in glomerular capillary regeneration.
More recently, a subset of hematopoietic stem cells, featured
by the expression of the surface molecules CD24+/CD133+,
has been shown promising as it was able to regenerate
both tubular cells and podocytes. This is quite signiﬁcant
because the depletion of these cells plays a crucial role
in the development of glomerulopathies which are now
believed to be podocytopathies [71]. However, in the context
of cell-therapy approaches for diabetic nephropathy, the
most attractive candidates seem to be the MSC. So far,
several works have shown that MSC administration can both
prevent and treat diabetic nephropathy. In mice with type
1D M[ 72], MSC had the ability to induce β pancreatic
islets regeneration with consequent achievement of a better
glycemic control that, in turn, prevented the development of
diabetic nephropathy. MSC also had the ability to slow the
progression of diabetic nephropathy through mechanisms
independent from glycemic control [73]( Figure 2). Indeed,
after an infusion of MSC, 11% of these cells engrafted
into the kidneys, where they diﬀerentiated into endothelial
cells and possibly mesangial cells. This was associated
with a signiﬁcant decrease in mesangial thickening, extra-
cellular matrix deposition, and macrophages inﬁltration
[74].
5.2. Diabetic Neuropathy. Diabetic neuropathy is estimated
to aﬀect over half of the patients with DM. It is a form
of neuropathy that aﬀects the somatic and autonomic
divisions of the peripheral nervous system, but the spinal
cord and the higher central nervous system can also be
damaged. The main underlying cause is glucotoxicity and its
downstream eﬀects [1]. High glucose levels, oxidative stress,
and AGEs reduce nerve blood ﬂow and impair neurotrophic
support, altogether leading to neural cells degeneration.
Cell-basedapproachespromotingendogenousproductionof
neurotrophic factors, such as nerve growth factor (NGF),Experimental Diabetes Research 5
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Figure 1:EﬀectsofMSCandEPConmyocardialrepair/regenerationandangiogenesis.TheactivitiesofMSCandEPCmayderivefromtheir
diﬀerentiative ability (into cardiomyocytes and/or endothelial cells) as well as from secretion of paracrine mediators promoting myogenesis,
angiogenesis, and heart functionality, in direct and/or indirect manners.
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Figure 2: Potential role of EPC and MSC in the control of diabetic microvascular complications and wound healing. Diabetes mellitus
is characterized by microvascular complications (retinopathy, nephropathy, and neuropathy) and prolonged/incomplete wound healing.
Cell-based therapies may control these complications by diﬀerent potential mechanisms.
hepatocyte growth factor (HGF), neurotrophin 3, or VEGF,
have recently shown some success [1]( Figure 2).
In the setting of diabetic neuropathy, both EPC and
MSC have been investigated. Many studies have shown that
transplantation of EPC ameliorates the blood ﬂow to periph-
eral ischemic tissues. Naruse and colleagues investigated
whether a unilateral intramuscular injection of EPC into
the hind limb skeletal muscles could ameliorate diabetic
neuropathy. After such transplantation, more vessels were
observed in the injected sites, and this was associated with
an amelioration of sciatic nerve blood ﬂow and motor nerve
conduction velocity. These data suggest that the ability of
EPC to treat diabetic neuropathy is due to the promotion of
therapeutic neovascularisation [75]( Figure 2). In addition,
in another study, intramuscularly injected EPC not only
increased nerve blood ﬂow but also increased the number of
vasa nervorum ameliorating the microvascular insuﬃciency
typical of diabetic neuropathy [76]. As a matter of interest,
in the same study, EPC were also found to increase the
production of VEGF-A, brain-derived neurotrophic factor,
ﬁbroblast growth factor (bFGF)-2, stroma-derived factor-1
(SDF-1),andotherneurotrophicfactors,thereforeindicating6 Experimental Diabetes Research
that EPC may reverse various manifestations of diabetic
neuropathy through both angiogenic and neurotrophic
properties (Figure 2). Consistent with this, in vitro studies
proved that EPC were able to make Schwann and endothelial
cells proliferate and to reduce the number of apoptotic cells
[76].
Also MSC have displayed angiogenic and neurotrophic
properties. Four weeks after their intramuscular injection,
MSC started producing bFGF and VEGF, and this was
associated with an increased ratio between capillaries and
muscular ﬁbers, an increased blood ﬂow to the sciatic nerve,
an improvement in motor nerve conduction velocity, and a
reduced hyperalgesia [77].Althoughoneofthemostexciting
properties of MSC, from a therapeutic perspective, is their
ability to diﬀerentiate into multiple cellular phenotypes,
any diﬀerentiation into neural cells, such as astrocytes,
oligodendrocytes, and Schwann cells, has not yet been
observed [77]( Figure 2).
5.3. Diabetic Retinopathy. DM is the leading cause of
cases of blindness among adults. Diabetic retinopathy is
characterized by a complex of vascular and retinal lesions,
all ultimately due to hyperglycemia. This disorder can be
categorized into the non proliferative diabetic retinopathy
(NPDR) and the proliferative diabetic retinopathy (PDR)
[1]. NPRD is characterized by vascular changes leading to
retinal ischemia, whereas PDR is the result of an aberrant
reactive neovascularisation. Most works carried out in this
ﬁeld have featured EPC, reporting a reduced number of
EPC in patients with NPDR [78, 79] but an increased
number of EPC in those with PDR. This is consistent with
the hypothesis that, since EPC can rescue and maintain
the existing retinal capillary bed in healthy patients, the
reduced number of EPC observed in DM might predispose
to NPDR [2]. Once the damage is initiated, an inﬂammatory
reaction will take place and the bone marrow will respond
by increasing the mobilization of EPC, which will eventually
result in an abnormal neovascularisation leading to PDR.
To date, the studies carried out on ischemic retinal injury
have documented the participation of adult stem cells in the
retinal repair, showing their ability to home into damaged
areas and to diﬀerentiate into endothelial cells, microglia,
and astrocytes [80–82]( Figure 2). However, these studies
were all conducted in animal models of ischemic retinal
injuryandsoconcernstillremainsabouttheviabilityofthese
therapeutic options in the long run, since they could worsen
the aberrant reactive neovascularisation featuring the PDR
that follows any ischemical retinal injuries. Therefore, PDR
may represent a contraindication for angiogenic cell-based
therapies.
5.4. Wound Healing. Another common complication of DM
is represented by the prolonged and incomplete wound
healing, caused by compromised angiogenesis, diminished
cells recruitment, lack of growth factors, and impaired
formation of collagen matrix. It has been demonstrated that
generally the number of MSC increases considerably in the
site of an injury, and that after a vascular trauma a rapid
mobilization to the injured site of EPC also takes place.
Wound healing normally results from a combined eﬀort of
inﬂammatory and noninﬂammatory cells recruited to the
injured site. Recent studies suggest that MSC and EPC are
a signiﬁcant proportion of the noninﬂammatory cells that
migrate to the skin. In DM, the number of EPC within
the granulation tissue has been found to be signiﬁcantly
reducedwithrespecttonondiabeticcontrols[83]andlocally
increased apoptosis and decreased proliferation of these cells
have also been reported. Several works have shown that MSC
accelerate wound closure by diﬀerentiating into ﬁbroblasts
and keratinocytes, and promoting neovascularisation and
regeneration of appendages and recruiting inﬂammatory
cellsintowounds[84,85](Figure 2).TransplantationofEPC
has also been shown to enhance wound healing in mice [86],
and this seems to rely on the release of paracrine mediators,
suchasthereleaseofVEGF,HGF,G-CSF,andPDGF[84,87].
As expected, in the setting of DM, the same mechanisms,
mentioned above for MSC and EPC, have been shown to
enhance wound healing [88, 89] and to also be an eﬀective
treatment of foot ulcerations [90–92]( Figure 2).
6.Genetic Manipulation and Pharmacological
Strategies Aimed at Reversing the Alterations
of Adult Stem/Progenitor Cells in Diabetes
6.1. Genetic Manipulation. The evidence obtained so far
makes for a compelling argument for the use of MSC and/or
EPC in the setting of DM [2]. Because of the broadly dys-
functionalcellfunctions foundin DM,it is believed thatcells
to be used for treatment of diabetic complications should
be equipped with cellular and molecular tools to make them
withstand the in vivo diabetic milieu. Thus, studies into the
genetic modiﬁcation and/or manipulation of diabetic cells
have commenced as approaches in overcoming this issue.
In recent work, Marrotte and colleagues [93]t r a n s f e c t e d
EPC with the gene of manganese superoxide dismutase, in
order to correct its decreased expression found in diabetic
EPC. They found that, after this ex vivo manipulation, the
EPC transplanted contributed signiﬁcantly to the accelerated
wound healing in a type 2 DM animal model. So far, several
molecules have been targeted, such as human telomerase
reverse transcriptase (hTERT), which was shown to delay
EPC senescence [94], and the glycogen synthase kinase 3-
β, which enhanced the EPC vasoregenerative potential [95].
In MSC, the overexpression of GATA-4, CXCR4, and Akt-1
led, respectively, to increased cell survival and angiogenesis
[96], enhanced in vivo mobilization into ischemic areas
[97], and better functional repair in a mouse infarct model
[98]. Although the genetic manipulation of adult stem
cells dysfunctions in DM has shown promising results,
one should be very cautious when adopting this approach
because of its potential side eﬀects. For instance, targeting
senescence/survival regulatory pathways warrants greater
understanding given the risk of malignant transformation of
the cells.
6.2.PharmacologicalStrategies. Otherapproacheshavephar-
macologically targeted the intracellular dysfunctions thatExperimental Diabetes Research 7
take place in DM. For example, the eﬀects of AVE9488
[99], GH [100], both stimulating eNOS, and those of
rosiglitazone, which has antioxidant properties [101]h a v e
beenstudiedastreatmentsforthereducedNObioavailability
[102]. Interestingly, Sorrentino and colleagues showed that
the eﬀect of rosiglitazone treatment was comparable to
that of small-interfering RNA silencing NADPH oxidase
subunit p47. Both approaches reduced NADPH oxidase
activity, restoring NO bioavailability, and improved in vivo
reendothelization capacity of EPC isolated from diabetic
patients. However, whether increasing NO production and
bioavailability may result in higher production of reactive
oxygen species that will further increase oxidative stress
leading to vascular damage is unknown yet. The blockade
of p38/MAPK pathway, using its speciﬁc inhibitor SB203580,
has also been assayed. Seeger and colleagues demonstrated
that the ex vivo treatment of EPC with SB203580 was able
to signiﬁcantly ameliorate their revascularisation properties,
possibly through the regulation of their proliferation and
diﬀerentiation [103]. Ex vivo treatment of MSC with IGF-
1 and IGF-2 made MSC regain the functions aﬀected by
DM [104]. Finally, antagonists of CXCR4 (such as AMD3100
and SDF-1βP2G), which disrupt the interaction between the
CXCR4 receptor (on hematopoietic cells) and the CXCL12
(expressed by stromal cells), have already been shown
promising in accelerating blood ﬂow restoration in diabetic
mice [105].
7. Conclusions
The past decade has provided new and fascinating in vitro
and in vivo data supporting the use of MSC and EPC for
thetreatmentofdiabeticcomplications.However,amongthe
issues raised, the possible contribution of these cells to lesion
formation,intermsofatherogenesis,neointimalhyperplasia,
and retinal aberrant angiogenesis, as well as the potential
risk of their malignant transformation will certainly require
further long-term analysis. Also, it is yet to deﬁne the best
way to make these cells withstand the diabetic milieu in the
long run. Therefore, a greater understanding of MSC and
EPC biology, both in in vitro and in vivo studies, is needed
to establish the safety of their use as a novel and eﬃcient
therapeutic agents in the treatment of complications of DM.
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